E-mail: thomas.lion@ccri.at
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- DEFINING LOW AND UNDETECTABLE LEVELS OF DISEASE IN CHRONIC MYELOID LEUKAEMIA: PROGRESS TOWARDS STANDARDISATION IN EUROPE
- DEFINITIONS AND STANDARDISATION OF ‘COMPLETE’ MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA
- Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe
- Harmonized Testing for BCR-ABL1 Kinase Domain Mutations In CML: Final Results of a Survey and First Control Round within 24 National Reference Laboratories In Europe
- International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MR
- INTERNATIONAL STANDARDIZATION OF MINIMAL RESIDUAL DISEASE ASSESSMENT FOR PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA EXPRESSING MINOR-BCR-ABL: UPDATED RESULTS OF EUROMRD
- Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study
- Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds
- The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories
- The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories
- TREATMENT WITH NILOTINIB IN EARLY CHRONIC PHASE CML–FIRST RESULTS FROM THE ENEST1ST SUB STUDY CAMN107EIC01
